XCUR Exicure Inc
Price (delayed)
$12.3
Market cap
$77.71M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.75
Enterprise value
$70.41M
Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes its proprietary
Highlights
XCUR's equity has soared by 123% year-on-year
The debt has contracted by 14% YoY and by 4% from the previous quarter
The net income has dropped by 142% since the previous quarter but it is up by 43% year-on-year
Exicure's EPS has plunged by 128% from the previous quarter but it has soared by 55% YoY
Key stats
What are the main financial stats of XCUR
Market
Valuations
Earnings
Shares outstanding
6.32M
Market cap
$77.71M
Enterprise value
$70.41M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.95
Price to sales (P/S)
50.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
140.83
Revenue
$500,000
Gross profit
$500,000
Operating income
-$12.23M
Net income
-$9.7M
EBIT
-$9.68M
EBITDA
-$8.85M
Free cash flow
-$2.91M
Per share
Balance sheet
Liquidity
EPS
-$4.75
EPS diluted
-$4.75
Free cash flow per share
-$1.42
Book value per share
$3.12
Revenue per share
$0.24
TBVPS
$7.37
Total assets
$15.06M
Total liabilities
$8.28M
Debt
$5.21M
Equity
$6.77M
Working capital
$10.6M
Debt to equity
0.77
Current ratio
4.45
Quick ratio
4.24
Net debt/EBITDA
0.82
Margins
Efficiency
Dividend
EBITDA margin
-1,770.2%
Gross margin
100%
Net margin
-1,940.2%
Operating margin
-2,446.4%
Return on assets
-82.4%
Return on equity
-319.7%
Return on invested capital
-88.7%
Return on capital employed
-80.7%
Return on sales
-1,935%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
XCUR stock price
How has the Exicure stock price performed over time
Intraday
-6.82%
1 week
-11.57%
1 month
30.16%
1 year
301.96%
YTD
-10.02%
QTD
-7.8%
Financial performance
How have Exicure's revenue and profit performed over time
Revenue
$500,000
Gross profit
$500,000
Operating income
-$12.23M
Net income
-$9.7M
Gross margin
100%
Net margin
-1,940.2%
The net margin has plunged by 142% from the previous quarter
The net income has dropped by 142% since the previous quarter but it is up by 43% year-on-year
Exicure's operating margin has shrunk by 99% QoQ
XCUR's operating income has dropped by 99% since the previous quarter but it is up by 18% year-on-year
Growth
What is Exicure's growth rate over time
Valuation
What is Exicure stock price valuation
P/E
N/A
P/B
3.95
P/S
50.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
140.83
Exicure's EPS has plunged by 128% from the previous quarter but it has soared by 55% YoY
XCUR's equity has soared by 123% year-on-year
XCUR's P/B is 36% above its 5-year quarterly average of 3.1 and 36% above its last 4 quarters average of 3.1
The stock's price to sales (P/S) is 154% more than its last 4 quarters average of 21.2
Efficiency
How efficient is Exicure business performance
Exicure's ROIC has plunged by 197% from the previous quarter but it has increased by 10% YoY
Exicure's ROS has plunged by 143% from the previous quarter
The ROA has plunged by 124% from the previous quarter but it has grown by 20% YoY
XCUR's ROE has shrunk by 67% QoQ and by 51% YoY
Dividends
What is XCUR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for XCUR.
Financial health
How did Exicure financials performed over time
The company's total assets is 82% higher than its total liabilities
The company's total assets rose by 42% QoQ and by 30% YoY
Exicure's total liabilities has decreased by 9% QoQ and by 3.1% YoY
The debt is 23% less than the equity
XCUR's equity has soared by 123% year-on-year
Exicure's debt to equity has shrunk by 78% QoQ and by 61% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.